产品
编 号：F751009
分子式：C26H19ClF3NO6S
分子量：565.95
分子式：C26H19ClF3NO6S
分子量：565.95
产品类型
规格
价格
是否有货
结构图
CAS No: 2304859-34-3
产品详情
生物活性：
Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-density lipoprotein cholesterol (LDLC) and promotion of high-density lipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats.
体内研究：
Lipid-lowering agent-1 (15 mg/kg; i.g., daily for 40 or 80 days) reduces blood cholesterolby, triglycerides and LDLC by 19.6%, 34.52%, and 41.49% after dosing 40 days, moreover the three indexes is still better than that of berberine after dosing 80 days.Animal Model:High-fat diet (HFD) rats
Dosage:15 mg/kg
Administration:i.g., daily for 40 or 80 days
Result:Reduced blood cholesterolby, triglycerides and LDLC by 19.6%, 34.52%, and 41.49% after dosing 40 days, moreover the three indexes was still better than that of berberine after dosing 80 days.
体外研究：
Lipid-lowering agent-1 (compound 1m) (12.5 μM; 72 hours) does not exhibit significant toxicity to both HepG2 and 3T3-L1 cells at a high concentration.Lipid-lowering agent-1 (10 μM; 24 hours) has significant pharmacological effects on the inhibition of LDLC and promotion of HDLC production.Lipid-lowering agent-1 (10 μM; 24 hours) inhibits the conversion of 3T3-L1 cells from pre-adipose to adipose-like with the inhibition of triglycerides (TG) by 70.4%.Lipid-lowering agent-1 (10 μM; 10 days) decreases yellow lipid droplets effectively in 3T3-L1 cells.
Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-density lipoprotein cholesterol (LDLC) and promotion of high-density lipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats.
体内研究：
Lipid-lowering agent-1 (15 mg/kg; i.g., daily for 40 or 80 days) reduces blood cholesterolby, triglycerides and LDLC by 19.6%, 34.52%, and 41.49% after dosing 40 days, moreover the three indexes is still better than that of berberine after dosing 80 days.Animal Model:High-fat diet (HFD) rats
Dosage:15 mg/kg
Administration:i.g., daily for 40 or 80 days
Result:Reduced blood cholesterolby, triglycerides and LDLC by 19.6%, 34.52%, and 41.49% after dosing 40 days, moreover the three indexes was still better than that of berberine after dosing 80 days.
体外研究：
Lipid-lowering agent-1 (compound 1m) (12.5 μM; 72 hours) does not exhibit significant toxicity to both HepG2 and 3T3-L1 cells at a high concentration.Lipid-lowering agent-1 (10 μM; 24 hours) has significant pharmacological effects on the inhibition of LDLC and promotion of HDLC production.Lipid-lowering agent-1 (10 μM; 24 hours) inhibits the conversion of 3T3-L1 cells from pre-adipose to adipose-like with the inhibition of triglycerides (TG) by 70.4%.Lipid-lowering agent-1 (10 μM; 10 days) decreases yellow lipid droplets effectively in 3T3-L1 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备